Every material Form 8-K Century Therapeutics, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Century Therapeutics presented nonclinical data on its iPSC-derived islet replacement therapy CNTY-813 at the European Association for the Study of Diabetes meeting in Milan on October 2, 2026. The company reiterated that its CNTY-813 IND submission remains on track for the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.
Data showed CNTY-813 maintained glycemic control in diabetic mice for over eleven months until graft removal.
Five clinical-scale manufacturing batches produced consistent final product, using a 29-day process.
IND submission is expected in Q4 2026; initial clinical data are anticipated in 2H 2027.
The filing reports no financial results; the update covers preclinical data and development timing only.
Century Therapeutics added Joseph Truitt, chief executive of iECURE, Inc., as a director effective September 9, 2026, increasing the board from six to seven members. Truitt will also serve on the Compensation Committee and receive standard non-employee director pay, including a stock option award and an annual cash retainer, so the appointment adds a board member with biotechnology executive experience.
Truitt appointed effective September 9, 2026 as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders
Board size increased from six to seven directors; Truitt will serve on the Compensation Committee
Initial option grant of 148,000 shares of common stock, vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000
Board determined Truitt is independent under Nasdaq listing rules
Century Therapeutics reported a second-quarter 2026 net loss of $34.6 million, up from $32.5 million a year earlier, with no collaboration revenue in either period. Cash, cash equivalents and investments were $197.2 million at June 30, 2026, which the company says supports operations into 1Q 2029. For shareholders, the wider loss is offset in part by lower research and development and general and administrative spending, and the company reiterated an IND submission for CNTY-813 in the fourth quarter of 2026.
Q2 2026 net loss was $34.6 million, versus a net loss of $32.5 million in Q2 2025; net loss per share was $0.17 versus $0.38, on 205.8 million weighted average shares versus 86.2 million.
R&D expenses fell to $19.6 million from $26.9 million, and G&A expenses fell to $5.8 million from $7.8 million, which the company attributed to personnel and facility reductions.
A $11.1 million loss on lease component termination was recorded in Q2 2026, and the six-month period showed a net loss of $56.2 million versus net income of $44.0 million a year earlier, when collaboration revenue was $109.2 million.
The company stated that the CNTY-813 IND submission remains on track for 4Q 2026, with initial clinical data expected in 2H 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Century Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →